ecancermedicalscience

Review

Brachytherapy reirradiation for local recurrences of gynaecological cancers: two clinical cases, literature review and OAR constraints

12 Mar 2026
Javier Faundez, Carlos Schananier, Cynthia Villegas, Javier Retamales

Background: Local recurrence of gynaecological malignancies after prior pelvic radiotherapy presents a complex therapeutic dilemma. Pelvic exenteration is curative in select cases but carries high morbidity and profound quality-of-life impact. Salvage reirradiation with image-guided brachytherapy (BT) offers a highly conformal alternative; however, data remain fragmented and practical organ-at-risk (OAR) constraints are not standardised.

Objectives: 1) To describe in detail two contemporary cases of high-dose-rate (HDR) BT reirradiation – one vulvar and one vaginal vault recurrence – highlighting planning strategy, catheter implantation, dosimetry and clinical outcome; 2) to synthesise current evidence on efficacy, toxicity, dose–fractionation and technique of BT reirradiation in cervical, endometrial and vulvar cancers; and 3) to propose pragmatic cumulative EQD2 OAR limits for rectum, bladder, small bowel and urethra based on published series.

Methods: Both patients underwent computed tomography/magnetic resonance imaging-based contouring with hybrid interstitial or surface mould applicators. Total doses were 45.6 Gy in 8 fractions (EQD210 ≈ 60 Gy) for the vulvar recurrence and 24.6 Gy in 3 fractions (EQD24.5 ≈ 48 Gy) for the vaginal vault recurrence, with cumulative OAR doses referenced against literature-derived thresholds. A narrative review (1993–2024) identified 35 key studies involving >600 reirradiated patients.

Results: The vulvar case achieved complete response at 6 months without Grade ≥3 toxicity; the vaginal vault case showed initial partial response, remained ECOG 0 and required systemic therapy for later progression. Across the literature, 1- to 3-year local control ranged 40%–80% and overall survival 40%–60%, with severe late toxicity generally ≤30% when cumulative doses respected D2cc ≈ 70–100 Gy3 (rectum), 90–120 Gy3 (bladder) and D0.5cc ≤ 110 Gy3(urethra). Fractionation of 4–6 Gy BID for 5–10 fractions (EQD210 ≈ 40–50 Gy) was most common.

Conclusion: HDR BT reirradiation can achieve meaningful, sometimes durable, local control in carefully selected gynaecologic-cancer recurrences while preserving pelvic organs. Adhering to proposed cumulative EQD2 OAR constraints and employing image-guided interstitial techniques are paramount to curtail severe complications. Multidisciplinary assessment and treatment at experienced centres are strongly recommended to optimise outcomes.

Related Articles

Monali Swain, Sarbani Ghosh-Laskar, Lachlan McDowell, Christina Henson, Pierluigi Bonomo, Sadhana Kannan, Timothy Malouff, Akihiro Homma, Alexander Rühle, Anna Lee, Francesca Caparrotti, James Bates, Jorgen Johansen, Juliette Thariat, Marco Ferrari, Miguel Mayo-Yáñez, Sarah Hamilton, Sue S Yom, Hisham Mehanna, Petr Szturz
Catalina Vargas Añazco, Álvaro Torres Soto, Renata Soto Díaz, Martín Urra, Maite Azócar, Mauricio Camus Appuhn, Francisco Dominguez Covarrubias, César Sánchez Rojel, Francisco Acevedo Claros
Ahmed Sohaib, Enas Elkhouly, Gehad Elsheikh, Mahmoud Sweid, Alaa Shawkat, Hany Moawad, Muhammad Abulfadl, Amira Hegazy
Ariel Cherro, Laura Aresca, María Susana Ciruzzi, Alejo Agranatti, María Fernanda Montaña, Cynthia Frahne, Jaqueline Cimerman
Meghal Prajapati, Anil Kumar Goel, Yamini Patel, Divyeshkumar Rana, S Lokesh, Pooja Panchal, Dhruv Rathod, Chandramouli Ramalingam, Kondeti Ajay Kumar